Rising costs, unpredictable policies, and dwindling incentives are forcing Big Pharma to rethink the UK, with leading firms pausing multi-million-pound R&D projects, but why is the country losing its competitive edge?
Lauren Matelski, Jeremy MacMahon, and Pamela J. Lein from the University of California, Davis, weigh the risks associated with COVID-19 vaccines versus the benefits.
Aarthi JanakiRaman, Research Director, Chemicals and Advanced Materials at TechVision, Frost & Sullivan, explains how glycoscience offers opportunities galore in healthcare.
Five new COVID-19 research projects will study the durability of vaccine responses, low responses linked with health conditions and the effect of booster shots.
The UK Government has signed a contract for 35 million more doses of the Pfizer/BioNTech COVID-19 vaccine, to be delivered from the second half of 2022..
Rick Clayton, Technical Director, AnimalhealthEurope, in the final chapter of this three-part series, examines the benefits of benchmarking regulatory systems and promoting Good Regulatory Practice.
According to a new study, fenofibrate, a drug used to treat abnormal levels of fatty substances in the blood, could reduce COVID-19 infection by up to 70%.
The Joint Committee on Vaccination and Immunisation (JCVI) has recommended that all 16 and 17-year-olds should receive their first dose of the Pfizer-BioNTech vaccine.
